Patents by Inventor Alfica Sehgal

Alfica Sehgal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Serpina1 siRNAs: compositions of matter and methods of treatment
    Patent number: 10935917
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina 1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina 1.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: March 2, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • Serpina1 iRNA compositions and methods of use thereof
    Patent number: 10920223
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: February 16, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin A. Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20210041823
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 11, 2021
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica SEHGAL, David BUMCROT, Brian BETTENCOURT
  • ASSAYS AND METHODS FOR DETERMINING EXPRESSION OF THE LECT2 GENE
    Publication number: 20200339987
    Abstract: The invention relates to methods and assays for determining the activity or expression of LECT2 gene in a subject.
    Type: Application
    Filed: November 8, 2018
    Publication date: October 29, 2020
    Inventors: Gregory Hinkle, Ho-Chou Tu, Alfica Sehgal
  • METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS, IN PARTICULAR OTC DEFICIENCY
    Publication number: 20200316038
    Abstract: The present invention provides methods and compositions for the treating a patient with a urea cycle disorder. Methods and compositions are also provided for modulating genes encoding enzymes that participate in the urea cycle by altering gene signaling networks.
    Type: Application
    Filed: October 9, 2018
    Publication date: October 8, 2020
    Inventors: Alfica Sehgal, Alla A. Sigova, Igor Zlobine, Brian E. Schwartz, David A. Bumcrot
  • SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200216844
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.
    Type: Application
    Filed: December 14, 2018
    Publication date: July 9, 2020
    Inventors: Akin Akinc, Alfica Sehgal, Ivanka Toudjarska, Donald Foster, Stuart Milstein, Brian Bettencourt, Martin A. Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • METHODS OF TREATING LIVER DISEASES
    Publication number: 20200208128
    Abstract: The present invention provides methods and compositions for the treating a patient with one or more conditions associated with PNPLA3 such as nonalcoholic fatty liver disease (NAFLD) nonalcoholic steatohepatitis (NASH), and/or alcoholic liver disease (ALD). Methods and compositions are also provided for modulating the expression of the PNPLA3 gene in a cell by altering gene signaling networks.
    Type: Application
    Filed: August 14, 2018
    Publication date: July 2, 2020
    Inventors: David A. Bumcrot, Alfica Sehgal, Alla Sigova, Brian Elliott Schwartz, Gavin Whissell
  • Serpina1 iRNA compositions and methods of use thereof
    Patent number: 10683504
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: June 16, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin A. Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • Compositions and methods directed to treating liver fibrosis
    Patent number: 10669303
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: June 2, 2020
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Gregory Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200080085
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Application
    Filed: November 11, 2019
    Publication date: March 12, 2020
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin A. Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20190354055
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpinal gene, and methods of using such dsRNA compositions to inhibit expression of Serpinal.
    Type: Application
    Filed: July 17, 2019
    Publication date: November 21, 2019
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20190316127
    Abstract: The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Application
    Filed: May 23, 2019
    Publication date: October 17, 2019
    Inventors: Mark K. Schlegel, Maja Janas, Vasant R. Jadhav, Donald Foster, Muthiah Manoharan, Kallanthottathil G. Rajeev, Alexander V. Kel'in, Klaus Charisse, Jayaprakash K. Nair, Martin A. Maier, Shigeo Matsuda, Muthusamy Jayaraman, Alfica Sehgal, Christopher Brown, Kevin Fitzgerald, Stuart Milstein
  • ASSAYS AND METHODS FOR DETERMINING ACTIVITY OF A THERAPEUTIC AGENT IN A SUBJECT
    Publication number: 20190292595
    Abstract: The invention relates to methods and assays for determining the activity of a composition comprising a therapeutic gene administered to a subject.
    Type: Application
    Filed: February 6, 2019
    Publication date: September 26, 2019
    Inventors: Dinah Sah, David A. Bumcrot, Alfica Sehgal
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE
    Publication number: 20190119674
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LECT2 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of LECT2.
    Type: Application
    Filed: August 2, 2018
    Publication date: April 25, 2019
    Inventors: Brian Bettencourt, Kevin Fitzgerald, Gregory Hinkle, Alfica Sehgal
  • COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS
    Publication number: 20190016751
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Application
    Filed: February 26, 2018
    Publication date: January 17, 2019
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Greg Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180346910
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Application
    Filed: June 14, 2018
    Publication date: December 6, 2018
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin A. Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • Compositions and methods for inhibiting expression of the LECT2 gene
    Patent number: 10077444
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LECT2 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of LECT2.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: September 18, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Kevin Fitzgerald, Alfica Sehgal, Brian Bettencourt, Gregory Hinkle
  • Serpina1 iRNA compositions and methods of use thereof
    Patent number: 10030244
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: July 24, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20180120749
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Application
    Filed: December 15, 2017
    Publication date: May 3, 2018
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica SEHGAL, David BUMCROT, Brian BETTENCOURT
  • Compositions and methods directed to treating liver fibrosis
    Patent number: 9944671
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: April 17, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Greg Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva